arrow
B

Barnaby Hunt

ossian health economics and communications
H指数:22
被引数:1,381

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

每位达到复合治疗终点的患者年药房费用:Tirzepatide与1 mg皮下注射Semaglutide在2型糖尿病英国患者中的成本至目标分析

2026-03-020
OAAI
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW

每周一次的司美格鲁肽与安慰剂用于治疗丹麦2型糖尿病和慢性肾脏病的比较:一项基于FLOW研究的长期成本效益分析

2025-12-200
OAAI
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan (Dec, 10.1007/s13300-024-01675-7, 2024)

日本人群中2型糖尿病患者使用Tirzepatide 5 mg与Dulaglutide 0.75 mg治疗的长期能效比研究(Dec, 10.1007/s13300-024-01675-7, 2024)

2025-02-070
OA
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes
2024-09-160
OAAI